National Comprehensive Cancer Network
|
|||||
- Educational Events & Programs
- NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- NCCN Annual Congress: Hematologic Malignancies™
- NCCN Congress Series™
- NCCN Guidelines Update Webinar Series™
- NCCN Academy for Excellence & Leadership in Oncology™
- NCCN On-line CME/CE
- NCCN Library of Case Studies™
- NCCN Oncology Case Management Program™
- NCCN Oncology Policy Program
- NCCN International Programs
Recent Updates to NCCN Guidelines®
NCCN Categories of Evidence and Consensus
NCCN Guidelines® Steering Committee
Submission Request to the NCCN Guidelines Panels
Submission Request History
NCCN Guidelines Panels-Meeting Schedule
Permissions Requests
NCCN Compendium®
About the NCCN Compendium®
NCCN Compendium™ Chapters By Disease
Transparency: Process and Recommendations
No Longer Recommended Uses
NCCN Templates®
JNCCN – The Journal of the National Comprehensive Cancer Network
Subscribe Now
FAQ
JNCCN Task Force Supplements
NCCN Guidelines® & Clinical Resources
Submission Request to the NCCN Guidelines Panels
These documents will open in a new browser window.
Breast Cancer Panel
Chronic Myelogenous Leukemia Panel
Colon/Rectal/Anal Cancers Panel
- Bevacizumab - Submitted by Genentech on 6/8/2010
- Cetuximab - Submitted by Bristol-Myers Squibb on 5/16/2011
- Capecitabine (Colon Cancer) - Submitted by Genentech on 6/7/2011
- Capecitabine (Rectal Cancer) - Submitted by Genentech on 6/7/2011
Hodgkin Lymphoma Panel
Kidney/Testicular Cancers Panel
Melanoma Panel
- Ipilimumab - Submitted by Bristol-Myers Squibb on 3/25/2011
- Vemurafenib - Submitted by Genentech on 8/22/2011
Neuroendocrine Tumors Panel
- Sunitinib - Submitted by Pfizer Oncology on 8/18/2009
- Everolimus - Submitted by Novartis Pharmaceuticals Corporation on 9/8/2010
- Sunitinib - Submitted by Pfizer Oncology on 2/25/2011
Non-Hodgkin`s Lymphomas Panel
- Fludarabine - Submitted by sanofi-aventis on 4/5/2010
- Alemtuzumab - Submitted by Genzyme on 5/10/2010
- Ibritumomab - Submitted by Spectrum Pharmaceuticals, Inc. on 5/12/2010
- Bortezomib - Submitted by Millennium on 5/25/2010
- Rasburicase - Submitted by sanofi-aventis on 5/25/2010
- Pralatrexate - Submitted by Allos Therapeutics on 6/2/2010
- Rituximab - Submitted by Genentech on 6/8/2010
- Rituximab - Submitted by Genentech on 1/11/2011
- Brentuximab Vedotin - Submitted by Seattle Genetics on 8/19/2011
Non-Small Cell Lung Cancer Panel
- Erlotinib - Submitted by Genentech on 6/18/2010
- Erlotinib-Bevacizumab - Submitted by Genentech on 6/18/2010
- Erlotinib - Submitted by Genentech on 6/9/2011
Ovarian Cancer Panel
Pancreatic Adenocarcinoma Panel
- Paclitaxel - Submitted by Abraxis on 2/9/2010
- Docetaxel - Submitted by sanofi-aventis on 7/12/2010
- Oxaliplatin - Submitted by sanofi-aventis on 7/12/2010
Prostate Cancer Panel
E-mail
Print
Mark
Privacy Policy| Legal Notices| Site Map| Contact Us| Help
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved